The ITC ruled in favor of medical device maker Masimo, saying Apple infringed patents related to pulse oximetry, a technology used to measure blood oxygen levels. The ITC also concluded that the violation harmed the domestic industry.
Apple’s objection is based on two main arguments.
Apple argues that Masimo did not have a “domestic industry” at the time the complaint was filed. They note that the company is primarily focused on clinical pulse oximeters and does not have a smartwatch market.
Apple also argues that Masimo’s only evidence, CAD drawings of its W1 smartwatch (launched in 2022), does not qualify as a tangible “item” under ITC jurisdiction. They are talking about a precedent where 3D models are not considered imported goods.
Essentially, Apple argues that the ITC case lacks merit because there was no competing product at the time the complaint was filed and there is no material evidence. And all of this in 961 pages, yes.
Apple has expressed concern that a successful resolution of the Masimo case could set a dangerous precedent. They fear that other companies will also use the ITC process to attack competitors with “creativity and CAD” rather than an actual presence in the market.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
